BioSpace News Archive

Company’s Practices Oversee Care for the Complex, Chronically Ill Patients in National CMS Demonstration

The Bayer Trendlines Ag Innovation Fund (“the Fund”), set up by Bayer CropScience LP (“Bayer”) and The Trendlines Group Ltd. (“Trendlines”) (SGX: 42T) (OTCQX: TRNLY), announced the establishment of ProJini Agchem Ltd. (“ProJini Agchem”), a new company focused on developing a platform technology to develop novel pesticides with new modes of action

GNS Healthcare (GNS), a leading precision medicine AI company, announced today an extension of their Series D funding round, bringing the amount raised to $28 million, thanks to an investment from Merck Global Health Innovation Fund (GHI).

Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced that it will present at Biotech Showcase™ 2020, to be held January 13–15, 2020 at the Hilton San Francisco Union Square. Paragon Genomics CEO Tao Chen will give a corporate presentation and meet with investors.

Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the company’s novel approach to cell therapy and outline upcoming clinical development plans at the 38th Annual J.P. Morgan Healthcare Conference

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2020 on Wednesday, January 29, after the market closes.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on its TTI-621 and TTI-622 clinical programs.

Vivante Health, the leader in digital medicine for gut health and disease, proudly announced DebraAnn Braun has joined the company as Chief Technology Officer.

Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference